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962Roles of CD28, CTLA4, and Inducible Costimulator
in Acute Graft-versus-Host Disease in Mice
Jun Li,1,2 Kenrick Semple,2,3 Woong-Kyung Suh,4 Chen Liu,5 Fangping Chen,1
Bruce R. Blazar,6 Xue-Zhong Yu2,3T cells deficient for CD28 have reduced ability to expand and survive, but still cause graft-versus-host disease
(GVHD). Inducible costimulator (ICOS), a member of the CD28 family, is expressed on antigen-activated
T cells and plays unique roles in T cell activation and effector function. We hypothesized that ICOS contrib-
utes to the development of GVHD in the absence of B7:CD28/CTLA4 costimulation. In this study, we
evaluated the roles of CD28, CTLA4, and ICOS in the pathogenesis of acute GVHD after myeloablative
allogeneic bone marrow transplantation. Unexpectedly, we found that blocking CD28 and CTLA4 signals
using the clinically relevant reagent CTLA4-Ig increases the severity of GVHD mediated by CD41 T cells,
and that such treatment does not add any benefit to the blockade of ICOS. In contrast, selectively blocking
CD28 and ICOS, but not CTLA4, prevents GVHD more effectively than blocking either CD28 or ICOS
alone. Taken together, these results indicate that CD28 and ICOS are synergistic in promoting GVHD,
whereas the CTLA4 signal is required for T cell tolerance regardless of ICOS signaling. Thus, blocking
CD28 and ICOS while sparing CTLA4 represents a promising approach for abrogating pathogenic T cell
responses after allogeneic bone marrow transplantation.
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Graft-versus-host disease (GVHD) remains the
major complication of allogenic hematopoietic cell
transplantation (HCT), producing high morbidity and
mortality [1]. GVHD is initiated by mature donor
T cells that recognize disparate histocompatibility
antigens of the recipient. An efficient T cell response1Department of Hematology, Xiangya Hospital Central
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presenting cells (APCs) in addition to signals delivered
through the T cell receptor after recognition of a spe-
cific antigen [2]. CD28 has been well characterized
and is the most effective costimulatory molecule
expressed by na€ıve and activated T cells. Costimulation
through CD28 regulates multiple aspects of T cell
function, including cytokine secretion, proliferation,
and cell survival [3,4]. By using CD28-deficient mice,
we and others [5,6] have found that CD28
costimulation plays an important role in the
development of GVHD, although T cell activation
and GVHD can still proceed in the absence of CD28.
Furthermore, T cell responses to high-affinity or
high-abundance antigens, often present in transplant
recipients, are far less dependent on CD28 costimula-
tion than are T cell responses to low-affinity or low-
abundance antigens [7-9]. This makes it difficult to
induce transplantation tolerance by blocking the CD28
signal alone.
CTLA4, another member of the CD28 family,
competes with CD28 binding to the same ligands
(B7.1 and B7.2; B7 hereinafter) and delivers an inhib-
itory signal to T cell activation [10]. Inducible costi-
mulator (ICOS), the third member of the CD28
family [11], is expressed on T cell surface after activa-
tion and plays unique roles in T cell activation and
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immunoglobulin class switching [14,15]. ICOS ligand
B7h is constitutively expressed at low levels on APCs
and is up-regulated by tumor necrosis factor (TNF)-
a or lipopolysaccharides [16,17]. Additional studies
have suggested that CD28 and ICOS play distinct
roles in T cell differentiation, with the CD28 signal
responsible for T cell activation and the ICOS signal
responsible for certain effector functions [18-21].
In cardiac transplantation models, blockade of
B7h:ICOS interaction produced a modest but
significant prolongation of graft survival [20,22].
Efficiency was increased with delayed blockade as
opposed to early blockade, indicating an effect on
primed T cells [23]. Furthermore, the coblockade of
B7:CD28/CTLA4 and ICOS ligand:ICOS pathways
was significantly more effective in prolonging graft
survival than the blocking of either alone [22,24].
The role of ICOS in GVHD is complex. ICOS
blockade was found to exacerbate acute GVHD but
to inhibit chronic GVHD in a nonirradiated parent-
into-F1 model [25]; however, recent studies indicated
that ICOS blockade ameliorated GVHD in myleoa-
blative bone marrow transplantation (BMT) models
mediated by CD41 and CD81 T cells [26,27], with
distinct effects in CD41 versus CD81 T cells in one
model of single major histocompatibility complex
(MHC) antigen disparity [28]. In this study, we tested
the hypothesis that ICOS might play a significant role
in the development of GVHD in the absence of
B7:CD28/CTLA4 binding. We found that selectively
blocking B7:CD28 and ICOS ligand:ICOS while
sparing B7:CTLA4 interactions most effectively
prevented acute GVHD.MATERIALS AND METHODS
Mice
ICOS-deficient mice on a C57BL/6 (B6) back-
ground were kindly provided by Dr Chen Dong
(M.D. Anderson Cancer Center, Houston, TX)
[12,29]. CD28/ICOS-deficient mice on a B6 back-
ground were kindly provided by Dr TakMak (Ontario
Cancer Institute, Toronto, Canada). B6, B6.C-H2bm12
(bm12), B6.C-H2bm1 (bm1), CD28-deficient, and
B6.SJL-Ly5a Ptprca Pep3b (B6.Ly5.1) mice were pur-
chased from the Jackson Laboratory (Bar Harbor,
ME). (B6.Ly5.1  bm12)F1 mice were bred at the
H. Lee Moffitt Cancer Center and Research Institute
(Tampa, FL). All experimental procedures were
reviewed and approved by the Institutional Animal
Care and Use Committee.
T Cell Purification and Transplantation
Our protocol for T cell purification using
a magnetic cell separation system has been describedpreviously [6,28]. The purity of T cells used for
transplantation ranged from 91% to 97%. In
nonmyeloablative transplantation models, recipient
mice (B6.bm1) were exposed to 600 cGy of total-body
irradiation (TBI) at 120 cGy/min, a dose range that is
immunosuppressive but not lethal for this strain of
mice. Purified CD81 T cells from different donors on
a B6 background were suspended in phosphate-
buffered saline and injected via the tail vein into 7- to
8-week-old irradiated recipients within 24 hours after
irradiation. In myeloablative models, (B6  bm12)F1
mice were exposed to 1100-1200 cGy of TBI, and
BALB/c mice were exposed to 800-900 cGy of TBI.
T cell‒depleted (TCD) bone marrow (BM) cells alone
or in combination with purified Thy1.21 cells from
indicated donors were injected via the tail vein within
24 hours after irradiation. Recipient mice were
monitored every other day for clinical signs of GVHD
(eg, ruffled fur, hunched back, lethargy, diarrhea) and
for mortality.
Administration of Antibodies
Murine CTLA4-Ig and control L6-Ig (kindly
provided by Robert Peach, Bristol-Myers Squibb,
Princeton, NJ) were injected i.p. at 100 mg/mouse
every other day for 14 days starting on day 0, as
described previously [30]. Anti-ICOS monoclonal
antibody (mAb; hybridoma 7E.17G9.G1, rIgG2b,
produced at National Cell Culture, Minneapolis,
MN) or irrelevant rat IgG was injected i.p. at 200
mg/day from day 0 to day 5, then 3 times weekly up
to day 28 after BMT, as described previously [27].
Immunofluorescence Analysis
Two-, 3-, or 4-color flow cytometrywas performed
to measure the expression of surface molecules and in-
tracellular cytokines according to standard techniques.
Fluorescein isothiocyanate‒labeled anti-CD4, biotin-
labeled anti-Fas ligand (FasL), phycoerythrin-labeled
anti-CD4, anti-interferon (IFN)-g, anti‒TNF-a,
anti-IgG isotype control, and Cy-Chrome‒labeled
anti-CD4 were purchased from BD Pharmingen
(San Diego, CA). Phycoerythrin-labeled anti-IgG2a
was purchased from Caltag (Burlingame, CA). Biotin-
labeled anti-Ly5.1 mAb was prepared in our labo-
ratory. Biotinylated antibodies were detected with
streptavidin‒Cy-Chrome or streptavidin-APC. The
level of FasL expression is presented as mean fluores-
cence index (MFI), which equals themean fluorescence
intensity of cells stained with a specific mAb divided by
the mean fluorescence intensity of cells stained with
isotype control.
Cytokine and Histopathologic Analysis
Blood samples were obtained from BMT recipi-
ents at the specified times, and cytokine analysis was
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described previously [28]. Histopathology findings in
small intestine, liver, and skin were assessed by an
expert pathologist (C.L.) using coded samples as
described previously [31].
Statistical Analysis
For comparison of recipient survival among
groups in GVHD experiments, the log-rank test was
used to determine the statistical significance. The Stu-
dent t test was used to compare the engraftment and
expansion of donor T cells.RESULTS
Blocking Ligands of CD28 and CTLA4
Exacerbated GVHD Induced by CD41 T Cells
after Allogeneic BMT
It is generally believed that CD28 and ICOS deliver
positive costimulation to T cell responses, whereas
CTLA4 delivers negative costimulation. This concept
predicts that coblockade of CD28 and ICOS with spar-
ing of CTLA4 should lead to good control of T cell
alloresponses in transplantation; however, this has not
been proven in the context of allogeneic BMT. To
address the roles of CD28, ICOS, and CTLA4 in the
development of GVHD, we first examined the effect
of blocking CD28 and CTLA4 in the presence or ab-
sence of ICOS costimulation after myeloablative BMT
inmice. CTLA4-Ig was used to block B7 as an effective
CD28 and CTLA4 antagonist [32]. The B6/bm12
BMT model was initially used only with MHC II in-
compatibility between donor and recipient. CD41 cells
were purified fromwild-type (WT) or ICOS2/2 B6 do-
nors and injected into lethally irradiated bm12 mice.
These recipients were divided into 2 groups and treated
with L6-Ig or CTLA4-Ig. Consistent with results of
previous studies by our group and others [26-28],
ICOS2/2 CD41 T cells induced significantly delayed
GVHD (Figure 1A). Surprisingly, under these condi-
tions, treatment with CTLA4-Ig actually accelerated
theGVHDcausedbyWTCD41Tcells in bm12 recip-
ients comparedwith controls (P\ .01; Figure 1A); how-
ever, the treatment had no effect onGVHD induced by
ICOS2/2T cells. To confirm this result, we used a fully
MHC-mismatched B6/BALB/c BMT model, and
found that treatment with CTLA4-Ig also accelerated
the GVHD induced by CD41 donor T cells (P\ .05;
Figure 1B). These data differ from those reported by
other studies demonstrating that blocking B7:CD28/
CTLA4 interactions results in a reduction of GVHD,
rather than acceleration [33-37]. The major difference
between our current study and the previous studies
is that GVHD was induced only by CD41 T cells in
our study, whereas GVHD was induced by both
CD41 and CD81 T cells in the other studies. In ourstudy, negative regulation through CTLA4 dominated
the positive regulation through CD28 on CD41
T cells, which is consistent with 2 recent reports
indicating that B7 plays an essential role in tolerance
on alloreactive CD41 T cells in MHC II‒mismatched
transplantation models [38,39]. The dominant
negative role of CTLA4 over the positive role of
CD28 on CD41 T cells might be attributed to the
down-regulation of immune responses through
B7:CTLA4 ligation on effector T cells via T cell‒
T cell or T cell‒T regulatory cell interactions [40,41].
To gain insight into the underlying mechanisms,
we measured T cell activation and expansion in the
myeloablative B6/bm12 BMT model. In 6-day
T cell transfer experiments, the absolute numbers of
WT donor T cells (CD41Ly5.12) were 4.8 6 2.1 
105/spleen in the recipients treated with L6-Ig and
6.7 6 2.0  105/spleen in those treated with
CTLA4-Ig. The absolute numbers of ICOS2/2 donor
T cells were 8.1 6 0.4  105/spleen in the recipients
treated with L6-Ig and 3.56 1.2 105/spleen in those
treated with CTLA4-Ig. There was no significant dif-
ference (P. .05) between any 2 groups, indicating that
the CD28, CTLA4, and/or ICOS signals had no sig-
nificant effect on the early expansion of donor CD4
T cells. These data are in agreement with the previous
findings of our group and others showing that blocking
ICOS had no effect on T cell proliferation [26,28].
Given that blockade of CD28 reduces T cell
proliferation, we reasoned that additional CTLA4
blockade would reverse the effect of CD28 blockade,
and thus the combinational blockade of CD28,
CTLA4, and ICOS had no significant impact on
CD41 T cell proliferation in vivo.
We also measured the expression of IFN-g,
TNF-a, and FasL, each of which plays an important
role in the induction of GVHD by donor CD41 cells.
Six days after BMT, we evaluated donor T cells in re-
cipient spleen for the intracellular expression of IFN-g
andTNF-a (% positive cells) and surface expression of
FasL (MFI) (Figure 1C). In separate experiments, we
assessed how Th1/Th2 cytokines were affected by
the blockade of CD28, ICOS, or both by measuring
interleukin (IL)-2, IL-4, IL-5, IFN-g, and TNF-a in
recipient sera 14 days after BMT (Figure 1D). On
day 6, we found that treatment with CTLA4-Ig
increased expression of IFN-g, TNF-a, and FasL on
WT T cells compared with treatment with L6-Ig
(P \ .05 for each effector molecule) (Figure 1C).
Our data support the idea that coblockade of CD28
and CTLA4 accelerated GVHD induced by CD41
T cells (Figure 1A and B). Absence of ICOS
(ICOS2/2T cells) had little or no effect on the expres-
sion of these effector molecules at the single cell level
on day 6 (Figure 1C), but significantly suppressed pro-
duction of TNF-a and IFN-g, but not of IL-5, in re-
cipient sera on day 14 (Figure 1D). These results
Figure 1. Roles of CD28, CTLA4, and ICOS in GVHD induced by CD4 T cells in a myeloablative BMTmodel. Lethally irradiated (B6.Ly5.1 bm12)F1
mice (A) or BALB/c mice (B) underwent transplantation with TCD-BM alone or TCD-BM plus purified CD41 cells at 1  106/mouse from WTor
ICOS2/2 B6 donors. L6-Ig or CTLA4-Ig was injected i.p. at 100 mg/mouse every other day, for a total of 8 doses. Data were obtained for 1 experiment
in each model, and 5 or 6 mice were included in each group. (C) BMTwas set up as in (A), and recipient spleen was collected at 6 days after transplan-
tation. Splenocytes were stained individually for surface expression of FasL and intercellular expression of IFN-g and TNF-a, in combination with surface
expression of CD4 and Ly5.1. The expression of surface FasL (MFI) and intracellular IFN-g or TNF-a (% positive) are shown on gated CD41/Ly5.12
donor cells. The thin lines represent cells stained with isotype control mAb, and the thick lines represent specific mAbs for FasL. The results represent 2
replicate experiments. (D) BMTwas set up as in (A), with peripheral blood collected from each recipient on day 14. The levels of TNF-a, IFN-g, IL-5, IL-2,
and IL-4 in the recipient serum were measured as described in Materials and Methods. IL-2 and IL-4 were below detectable levels (data not shown).
The data were pooled from 2 replicate experiments, and each data point represents a cytokine concentration in one individual mouse.
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Figure 2. Roles of CD28 and ICOS in the development of GVHD induced by CD41 T cells in a myeloablative BMT model. Lethally irradiated BALB/c
mice underwent transplantation with TCD-BM alone or with TCD-BM plus 2  106 CD41 T cells from WTor CD28 KO B6 donors. A group of
recipients withWTor CD28 KO cells were treated with anti-ICOS mAb or irrelevant control, as described in Materials and Methods. Recipient survival
(A), weight loss (B), and pathology scores (C) are shown. The data are from one experiment with 5 or 6 recipients in each group; a similar outcome was
observed in another experiment in which T cell dose and anti-ICOS treatment differed somewhat.
966 Biol Blood Marrow Transplant 17:962-969, 2011J. Li et al.confirmed the previous findings by us and others
[26-28], indicating that the decreased production of
Th1 cytokines likely contributed to the reduced
ability of ICOS2/2 CD41 T cells to cause GVHD.
CTLA4-Ig treatment on ICOS2/2Tcells significantly
decreased IFN-g (P\ .05) and FasL (P\ .01), but sig-
nificantly increased TNF-a (P\ .01) compared with
control treatment on day 6. Furthermore, the cytokine
profile on day 14 was similar in the recipients of
ICOS2/2 T cells treated with CTLA4-Ig and those
treated with L6-Ig (Figure 1D). Taken together, these
data might explain why treatment with CTLA4-Ig did
not further reduce GVHD induced by ICOS2/2
CD41 T cells (Figure 1A and B).Blocking ICOS (Anti-ICOS) and CD28
(Knockout) While Sparing CTLA4 Prevents
GVHD Mediated by CD41 T Cells
Our previous work showed that the CTLA4 signal
plays a protective role in GVHD development [5,30].
Thus, we hypothesized that blocking ICOS and
CD28 while sparing CTLA4 would ameliorate
GVHD under conditions in which the absence of
CD28 alone was ineffective in preventing lethality.
To test this hypothesis, we used CD282/2 B6 mice
as donors and gave BALB/c recipients BM
supplemented with CD41 T cells and then treated
with antagonistic anti-ICOS mAb to block ICOS.
Using this strategy, we found that blockade of ICOS
(P 5 .002), but not the absence of CD28 alone
(P 5 .10), significantly delayed GVHD lethality in re-
cipients (Figure 2A). However, blockade of ICOS and
the absence of CD28 were able to prevent GVHD le-
thality in .80% of recipients and significantly reduce
weight loss more effectively than either blockade of
ICOS alone (P 5 .02) or the absence of CD28 alone
(P 5 .009) (Figure 2A and B). Furthermore, blockade
of ICOS and the absence of CD28 significantly im-
proved pathology scores in intestine, liver, and lung
tissues compared with intact costimulation, blockade
of ICOS, or the absence of CD28 alone (Figure 2C).
We therefore concluded that CD28 and ICOS con-tribute synergistically to the development of GVHD
induced by CD4 T cells.Roles of CD28, CTLA4, and ICOS in T Cell
Expansion and Cytokine Production
To elucidate the mechanisms by which simulta-
neous blockade of CD28 and ICOS prevent GVHD,
wemeasured the expansionofdonorCD41Tcells in re-
cipient spleens.CD41Tcellswerepurified fromWTor
CD28-deficient B6 mice and transferred together with
TCD-BM from B6 Ly5.11 donors into irradiated
BALB/c recipients. Donor T cells were identified as
CD41H2b1Ly5.12 in recipient spleens at 6 days after
transplantation. The absolute number of donor CD41
cells was an average of 8.2 6 1.8  105 per mouse for
WT cells and 6.9 6 1.6  105 per mouse for CD28
knockout (KO) cells (P 5 .60), indicating that both
WT and CD28 KO CD41 T cells had a similar
potential to expand in vivo. Treatment with anti-ICOS
mAb actually increased the expansion of WT donor
CD41T cells (P5 .05; Figure 3A); however, treatment
with anti-ICOS reduced the expansion of CD28 KO
cells, because the absolute number of CD28 KO cells
was significantly lower than that of WT cells and
CD28 KO cells with control treatment (P \ .05;
Figure 3A). These results indicate that CD41T cell ex-
pansion depends on both CD28 and ICOS.
Th1 cytokines (ie, IFN-g andTNF-a) play a critical
role in GVHD induced by CD41 T cells [42,43]. We
investigated how serum cytokines are affected by the
blockade of CD28, ICOS, or both by measuring IL-2,
IL-4, IL-17, IFN-g, and TNF-a in recipient serum at
18 days after BMT (Figure 3B). At this time point,
the levels of IL-2, IL-4, and IL-17 were very low or
undetectable, and IFN-g was detectable but not signif-
icantly different among the groups (data not shown).
The absence of CD28 or blockade of ICOS alone
reduced TNF-a production, but this reduction was
not significant (P . .05; Figure 3B); however, the
absence of CD28 and blockade of ICOS significantly
reduced TNF-a production compared with either
factor alone (P 5 .01 in both cases; Figure 3B). Taken
Figure 3. Roles of CD28, CTLA4, and ICOS in GVHD induced by CD41 T cells. Lethally irradiated BALB/c mice underwent transplantation with
TCD-BM from normal B6 Ly5.11mice or TCD-BM plus purified CD41 cells fromWTor CD282/2 B6 donors. Half of the recipients were also treated
with anti-ICOS or control mAb. (A) Six days after BMT, recipient spleen was collected and stained for expression of CD4, Ly5.1, and H2b. Data are the
absolute number of donor T cells (CD41Ly5.12 H2b1) in individual mice (n 5 3 in each group), representing 1 of 2 replicate experiments in similar
settings. (B) In separate experiments as described in (A), recipient peripheral blood samples were collected at 3 weeks after BMT. The TNF-a level
in recipient serum is shown in individual mice (n 5 5 or 6 per group), and the data were pooled from 2 replicate experiments.
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ICOS, while sparing CTLA4 resulted in reduction of
T cell expansion and TNF-a production during devel-
opment of GVHD induced by donor CD41 T cells.Roles of CD28, CTLA4, and ICOS in GVHD
Mediated by CD81 or CD41 Plus CD81 T Cells
Because clinical HCT typically includes CD81
T cells, we investigated whether the absence of
CD28 and/or ICOS expression on donor CD81
T cells would influence GVHD lethality when WT,
CD28 KO, ICOS KO, or CD28/ICOS double-KO
(DKO) mice were used as the source of donor
CD81 T cells (Figure 4A). Cohorts of MHC class
I‒disparate bm1 mice were sublethally irradiated
and given purified CD81 T cells from one of the
aforementioned donor strains. Whereas donor
CD81 T cells from WT and ICOS KO mice had
comparable survival, recipients of CD28-deficient
CD81 T cells had significantly prolonged survivalFigure 4. Roles of CD28 and ICOS on GVHD induced by CD81 T cells alone
irradiated and underwent transplantation with 1 106 purified CD81 cells per
survival is shown, and the data are from 2 replicate experiments with 6-15 r
BALB/c mice underwent transplantation with TCD-BM alone or TCD-BM pl
and DKO B6 donors. Recipient survival is shown, and the data are pooled fro
KO vs WT; P\.001, ICOS KO vs WT; P 5 .70, CD28 vs ICOS; P 5 .06, DKO(P\ .01). However, CD81 T cells from DKO mice
did not further prolong survival. In previous studies
using the same model system, CD25-depleted
CD81 T cells from ICOS KO mice resulted in
a significantly reduced GVHD lethality rate [27].
Whether the difference between these 2 studies is
related to the use of a CD25-depleted versus
CD25-replete T cell graft is unknown. Nonetheless,
our findings indicate that the absence of ICOS did
not have a major effect on GVHD lethality in this
CD81 T cell‒mediated GVHD lethality model.
Because clinical HCT grafts contain both CD41
and CD81 T cells, we performed studies using B6
WT, CD28 KO, ICOSKO, and DKOmice as sources
of donorCD41 andCD81Tcells injected into lethally
irradiated BALB/c recipients with both MHC and mi-
nor histocompatibility antigen differences. As shown
in Figure 4B, CD282/2 or ICOS2/2 T cells induced
significantly less GVHD compared with WT T cells
(P \ .001). There was no difference in recipient
survival between CD282/2 and ICOS2/2 cellsor by both CD41 and CD81 T cells. (A) B6 bm1 mice were sublethally
recipient fromWT, CD28 KO, ICOS KO, and DKO B6 donors. Recipient
ecipients per group (P\.01, CD28 KO vs WT). (B) Lethally irradiated
us 1-2  106 T cells (CD4 and CD8) from WT, CD28 KO, ICOS KO,
m 3 replicate experiments with 11-16 mice per group (P\.001, CD28
vs CD28 KO; P 5 .01, DKO vs ICOS KO).
Figure 5. Roles of CD28 and ICOS on GVHD induced exclusively by
CD41 T cells or driven primarily by CD41 cells and facilitated by
CD81 T cells. (A) CD28 and ICOS signaling positively regulated T cell
responses to alloantigens and supported GVHD development in an
additive or synergistic manner, whereas CTLA4was a negative regulator.
(B) Blockade of B7 (both CTLA4 and CD28) resulted in hyperactivation
of the allogeneic T cell response. (C and D) Blockade of CD28 or ICOS
resulted in suppression. (E) Blockade of both CD28 and ICOS with spar-
ing of CTLA4 led to T cell tolerance.
968 Biol Blood Marrow Transplant 17:962-969, 2011J. Li et al.(P 5 .70). Moreover, DKO T cells induced less
GVHD than CD282/2 (P 5 .06) or ICOS2/2
(P 5 .01) T cells. Thus, in a CD41 T cell‒driven and
CD81 T cell‒facilitated model system that more
closely simulates clinical allogeneic HCT, the absence
of both CD28 and ICOS provided the highest GVHD
protective effects.DISCUSSION
Using murine BMT models, which are represen-
tative of clinical allogeneic HCT settings, we found
that CD28 and ICOS signaling positively regulated
T cell responses to alloantigens and supported
GVHD development in an additive or synergistic
manner, whereas CTLA4 was a negative regulator
(Figure 5A). In the situation where GVHD is exclu-
sively induced by CD41 T cells or driven primarilyby CD41 T cells and facilitated through CD81 T
cells, blockade of B7 (both CTLA4 and CD28) results
in hyperactivation of the allogeneic T cell response
(Figure 5B), blockade of CD28 or ICOS results in
suppression (Figure 5C and D), and blockade of
both CD28 and ICOS with sparing of CTLA4 leads
to T cell tolerance (Figure 5E).
An elegant in vitro study by Nurieva et al. [44]
showed that in the absence of positive costimulation
mediated by CD28 and ICOS, negative costimulatory
molecules including CTLA4 and PD-1 actively
instruct T cells to develop into tolerant cells, charac-
terized by inactivation of intrinsic signaling and
transcriptional programs. The current study extends
those in vitro findings in clinically relevant models of
GVHD and shows that T cell immunity and tolerance
are determined by the combination of costimulatory
signals. Our study also provides direct evidence to sup-
port the blocking of CD28 and ICOS signals with
sparing of CTLA4 signals as an effective approach to
prevent GVHD through manipulation of the CD28
family of costimulatory molecules in vivo. More
selective CD28 blockade, rather than a B7 blockade
(eg, belatacept and nonactivating CD28-specific anti-
bodies), has been produced [45,46], and a fully
humanized antibody against human ICOS has been
generated [47]. These reagents can be used in the
translation of our research finding into clinical practice
in allogeneic HCT.ACKNOWLEDGMENTS
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